169 related articles for article (PubMed ID: 22083830)
1. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
Alvarez HM; So OY; Hsieh S; Shinsky-Bjorde N; Ma H; Song Y; Pang Y; Marian M; Escandón E
Drug Metab Dispos; 2012 Feb; 40(2):360-73. PubMed ID: 22083830
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl₄-induced fibrogenesis in mice.
Mattos A; de Jager-Krikken A; de Haan M; Beljaars L; Poelstra K
J Control Release; 2012 Aug; 162(1):84-91. PubMed ID: 22659050
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
4. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice.
Mihara M; Koishihara Y; Fukui H; Yasukawa K; Ohsugi Y
Immunology; 1991 Sep; 74(1):55-9. PubMed ID: 1718855
[TBL] [Abstract][Full Text] [Related]
5. Expression and in vitro properties of guinea pig IL-5: comparison to human and murine orthologs.
Scott CW; Budzilowicz C; Hubbs SJ; Stein M; Sobotka-Briner C; Wilkins DE
Mediators Inflamm; 2000; 9(3-4):181-7. PubMed ID: 11132776
[TBL] [Abstract][Full Text] [Related]
6. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
7. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
8. PEGylation of interleukin-6 effectively increases its thrombopoietic potency.
Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Kaneda Y; Ohsugi Y; Mayumi T
Thromb Haemost; 1997 Jan; 77(1):168-73. PubMed ID: 9031469
[TBL] [Abstract][Full Text] [Related]
9. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.
Bansal R; Post E; Proost JH; de Jager-Krikken A; Poelstra K; Prakash J
J Control Release; 2011 Sep; 154(3):233-40. PubMed ID: 21664391
[TBL] [Abstract][Full Text] [Related]
10. Soluble cytokine receptors as carrier proteins: effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4.
Ma Y; Hurst HE; Fernandez-Botran R
J Pharmacol Exp Ther; 1996 Oct; 279(1):340-50. PubMed ID: 8859012
[TBL] [Abstract][Full Text] [Related]
11. Murine IL-4 is able to signal via chimeric human IL-4Ralpha/mouse gamma-chain receptor.
Myburgh E; Horsnell WG; Cutler AJ; Arendse B; Kubo M; Brombacher F
Mol Immunol; 2008 Mar; 45(5):1327-36. PubMed ID: 18029018
[TBL] [Abstract][Full Text] [Related]
12. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
Leong SR; DeForge L; Presta L; Gonzalez T; Fan A; Reichert M; Chuntharapai A; Kim KJ; Tumas DB; Lee WP; Gribling P; Snedecor B; Chen H; Hsei V; Schoenhoff M; Hale V; Deveney J; Koumenis I; Shahrokh Z; McKay P; Galan W; Wagner B; Narindray D; Hébert C; Zapata G
Cytokine; 2001 Nov; 16(3):106-19. PubMed ID: 11741351
[TBL] [Abstract][Full Text] [Related]
13. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
14. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes.
Kurlander RJ; Ellison DM; Hall J
J Immunol; 1984 Aug; 133(2):855-62. PubMed ID: 6736648
[TBL] [Abstract][Full Text] [Related]
15. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor.
Liu Y; de Waal Malefyt R; Briere F; Parham C; Bridon JM; Banchereau J; Moore KW; Xu J
J Immunol; 1997 Jan; 158(2):604-13. PubMed ID: 8992974
[TBL] [Abstract][Full Text] [Related]
16. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of human IL-10/Fc fusion protein expressed in Pichia pastoris.
Guo Y; Kang W; Zhong Y; Li R; Li G; Shen Y; Hu S; Sun J; Xiao W
Protein Expr Purif; 2012 Jun; 83(2):152-6. PubMed ID: 22484198
[TBL] [Abstract][Full Text] [Related]
19. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
[TBL] [Abstract][Full Text] [Related]
20. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
